Stock Monitor: Aerie Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 05, 2018 / Active-Investors.com has just released a free research report on Merck & Co., Inc. (NYSE: MRK). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=MRK as the Company's latest news hit the wire. On March 01, 2018, the Company declared that it will present data from studies of the Company's robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), and MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), at the Conference on Retroviruses and Opportunistic Infections (CROI 2018). The conference is taking place in Boston, Massachusetts from March 04-07, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), which also belongs to the Healthcare sector as the Company Merck. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=AERI
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Merck most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=MRK
Merck scientists will also present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy.
Data on Subgroup Analysis from Phase 3 Study of Doravirine/Lamivudine/TDF in HIV-1
Presentations at CROI 2018 will include Week-48 subgroup analysis from the pivotal Phase-3 DRIVE-AHEAD trial evaluating the efficacy and safety of doravirine (DOR), lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR/3TC/TDF) for the treatment of HIV-1 infection in treatment-naïve adults. Additionally, results from a Phase-1 study evaluating MK-8591 that potentially inhibits HIV reverse transcriptase through multiple mechanisms will be presented in a late breaking abstract session.
FDA Accepted NDA for Doravirine for Treatment of HIV-1 Infection
On January 08, 2018, the US Food and Drug Administration (FDA) accepted for review two New Drug Applications (NDAs) for doravirine for the treatment of HIV-1 infection in adults. The NDAs included data for doravirine as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR/3TC/TDF). The FDA had set a target action date of October 23, 2018, for both applications under the PDUFA.
Merck's Commitment to HIV/AIDS
In the mid-1980s, Merck began its clinical HIV research. The Company's scientists were among the first to discover and develop medicines for the treatment of HIV. Since the first HIV products became available nearly two decades ago, the Company has worked to expand access to its medicines, build healthcare infrastructure, and address health and development challenges around the world. Merck maintains longstanding efforts to deliver its medicines to those who need it most, including differential pricing, voluntary licensing, public-private partnerships, philanthropic programs, and continued research and development efforts in HIV. The Merck Foundation has contributed more than $122 million over the past 15 years to help address barriers to HIV care across the globe.
What is HIV/AIDS?
The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. In most cases, HIV is a sexually transmitted infection and occurs by contact with or transfer of blood, pre-ejaculate, semen, and vaginal fluids. Non-sexual transmission can occur from an infected mother to her infant through breast milk.
About Doravirine (MK-1439, DOR)
Doravirine is an investigational NNRTI being evaluated by Merck for the treatment of HIV-1 infection. DOR is being evaluated in several ongoing clinical trials both as a once-daily single-entity tablet in combination with other antiretroviral agents in a tailored regimen, and as a once-daily fixed-dose combination (DOR/3TC/TDF) in a complete single tablet regimen.
About MK-8591
MK-8591 is Merck's NRTTI, currently being evaluated in clinical trials for the treatment of HIV infection. Preclinical evidence indicates that MK-8591 inhibits HIV reverse transcriptase through multiple mechanisms that are different from any approved anti-HIV medicines, including traditional nucleoside reverse transcriptase inhibitors (NRTIs). MK-8591 is being evaluated in a 3-part Phase-2b dose-ranging trial, DRIVE2SIMPLIFY, a study of MK-8591 in combination with doravirine.
About Merck & Co., Inc.
Merck, known as MSD outside of the United States and Canada, is a leading global biopharmaceutical company that brings forward medicines and vaccines for many of the world's most challenging diseases. Headquartered in Kenilworth, New Jersey, the Company through its prescription medicines, vaccines, biologic therapies, and animal health products, works with customers and operate in more than 140 countries.
Stock Performance Snapshot
March 02, 2018 - At Friday's closing bell, Merck's stock rose 1.23%, ending the trading session at $54.36.
Volume traded for the day: 8.90 million shares.
After last Friday's close, Merck's market cap was at $147.59 billion.
Price to Earnings (P/E) ratio was at 29.87.
The stock has a dividend yield of 3.53%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 1.2% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
